DC Chemicals Limited
China
Product Name: Oxitropium Bromide
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,9-ethyl-7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9-methyl-, bromide (1:1), (1a,2b,4b,5a,7b)-
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

30286-75-0

30286-75-0 structure

30286-75-0 structure

Name: Oxitropium Bromide
Chemical Name: Tersigat
CAS Number: 30286-75-0
Molecular Formula: C₁₉H₂₆BrNO₄
Molecular Weight: 412.31800
Catalog: analytical chemistry Standard Pharmacopoeia Standards and Magazine Standards
Create Date: 2018-07-30 21:08:18
Modify Date: 2024-01-04 12:24:01
Oxitropium bromide is an mAChR antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.

Name	Tersigat
Synonyms	Oxivent Oxitropium Oxitropium bromide Ba-253-BR-L Ventilat oxytropium bromide Bromure d'oxitropium

Description	Oxitropium bromide is an mAChR antagonist used as an anticholinergic bronchodilator drug for the treatment of asthma and chronic obstructive pulmonary disease.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> Neuronal Signaling >> mAChR Research Areas >> Inflammation/Immunology
Target	mAChR[1]
In Vitro	Oxitropium bromide is a muscarinic antagonist which blocks musucarinic acetylcholine receptors (mAChR). Incubation with oxitropium bromide of untreated diaphragm muscle and diaphragm muscle injected with endotoxin does not increase the force-frequency curves dose-dependently in vitro; however, it causes both types of muscle to be fatigue resistant[1].
In Vivo	Oxitropium bromide inhalation shifts force-frequency curves upward at 2 h after inhalation and inhibits the decrease of force-frequency curves due to endotoxin injection in vivo[1]. Oxitropium bromide strongly and persistently inhibits the acetylcholine (ACh)-induced resistance. The increase in resistance induced by histamine, serotonin, leukotriene D4 or antigen is prevented by oxitropium bromide oxitropium bromide[2]. Inhalation of the anticholinergic agent oxitropium bromide at doses of 1.5 μg and higher greatly attenuates the decrease in mucus score produced by intravenous histamine but not by inhaled histamine[3].
Animal Admin	Mice: In the oxitropium bromide inhalation group, animals are given 2 puffs of inhalation from a oxitropium bromide MDI (metered dose inhaler) via a 75-mL spacer, and then diaphragm muscles are dissected and measured as to contractility immediately, 1 hour, 2 hours and 4 hours later (n=5 animals each). An animal is placed in a centrifugal tube (inner diameter=30 mm) with a round hole (diameter=10 mm) in the bottom, its nose and mouth being exposed through the hole to breath. An oxitropium bromide MDI (metered dose inhaler) releases 2 puffs into a spacer attached to the tube. Aerosols of oxitropium bromide are inhaled for about 10 seconds, while the animal is breathing spontaneously through the hole of the tube[1].
References	[1]. Shindoh C, et al. Effects of inhalation or incubation of oxitropium bromide on diaphragm muscle contractility in mice. Allergol Int. 2011 Sep;60(3):365-72. [2]. Kohno SW, et al. Effect of oxitropium bromide (Ba253) on increased airway resistance induced by various agonists and antigen in the guinea pig. Jpn J Pharmacol. 1989 Aug;50(4):455-66. [3]. Takeyama K, et al. Effect of oxitropium bromide on histamine-induced airway goblet cell secretion. Am J Respir Crit Care Med. 1996 Jul;154(1):231-6.

Melting Point	203-204° (dec)
Molecular Formula	C₁₉H₂₆BrNO₄
Molecular Weight	412.31800
Exact Mass	411.10500
PSA	59.06000

CHEMICAL IDENTIFICATION

RTECS NUMBER :: RN7090000

CHEMICAL NAME :: 3-Oxa-9-azoniatricyclo(3.3.1.0(sup 2,4))nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)- 9-methyl-, bromide, (7(S)-(1-alpha,2-beta,4-beta,5-alpha,7-beta))-

CAS REGISTRY NUMBER :: 30286-75-0

LAST UPDATED :: 199512

DATA ITEMS CITED :: 16

MOLECULAR FORMULA :: C19-H26-N-O4.Br

MOLECULAR WEIGHT :: 412.37

WISWESSER LINE NOTATION :: T C356 A AK DOTJ A2 A1 HOVYR&1Q &E

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2250 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 19 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - other changes

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1600 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1150 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 25700 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 40 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - changes in motor activity (specific assay) Lungs, Thorax, or Respiration - other changes

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: >8 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 35,435,1985

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 34 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 4,117,1979 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 55 gm/kg/13W-C

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 17 gm/kg/78W-C

TOXIC EFFECTS :: Gastrointestinal - decreased motility or constipation Related to Chronic Data - death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 2730 mg/kg/13W-C

TOXIC EFFECTS :: Sense Organs and Special Senses (Eye) - conjunctive irritation Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 36,353,1988 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 55 gm/kg

SEX/DURATION :: male 10 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 6600 mg/kg

SEX/DURATION :: female 7-17 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 7800 mg/kg

SEX/DURATION :: female 17-21 day(s) after conception lactating female 21 day(s) post-birth

TOXIC EFFECTS :: Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - behavioral

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2600 mg/kg

SEX/DURATION :: female 6-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death

REFERENCE :: OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 37,413,1989

74-96-4 structure

74-96-4

~%

30286-75-0 structure

30286-75-0

Literature: Journal of the American Chemical Society, , vol. 78, p. 3448,3452

74-83-9 structure

74-83-9

67009-40-9 structure

67009-40-9

~84%

30286-75-0 structure

30286-75-0

Literature: Banholzer; Pook Arzneimittel-Forschung/Drug Research, 1985 , vol. 35, # 1 A p. 217 - 228

114-49-8 structure

114-49-8

~%

30286-75-0 structure

30286-75-0

Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 1 A p. 217 - 228

24676-80-0 structure

24676-80-0

~%

30286-75-0 structure

30286-75-0

Literature: Arzneimittel-Forschung/Drug Research, , vol. 35, # 1 A p. 217 - 228

Precursor 5
74-96-4 74-83-9 67009-40-9 114-49-8
24676-80-0
DownStream 2
67009-40-9 51-34-3